COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19.
According to data from 25 state and local health departments, adults who were unvaccinated against COVID-19 as the omicron variant emerged in December had nearly three times higher risk of infection than adults fully vaccinated against COVID-19 and five times higher risk than adults who had…
The Food and Drug Administration yesterday expanded its medical device shortage list to include all blood specimen collection tubes and recommended health care providers, laboratory directors and others consider certain strategies to conserve their use.
AHA Rural Health Care Leadership Conference, as partners of the CDC & Project Firstline, is offering 25 scholarships to attend the conference.
The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels.
On Jan. 7, the U.S. Supreme Court held oral argument to consider the injunctions that
blocked the Centers for Medicare & Medicaid Services’ (CMS) rule requiring covered
facilities to ensure that their staff are vaccinated against COVID-19 (subject to medical
and religious exemptions).
The U.S. Supreme Court today held oral arguments on whether to allow the Centers for Medicare & Medicaid Services’ and Occupational Safety and Health Administration’s vaccine mandates to go into effect while appeals are heard in the courts of appeals.
The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code J0248 for the VEKLURY (remdesivir) antiviral medication when administered in an outpatient setting, following a recent statement from the National Institutes of Health COVID-19…
The Food and Drug Administration announced that five months is the recommended interval between a primary dosing regimen and booster for Moderna’s COVID-19 vaccine. Previously, the recommended gap was six months.
The Department of Health and Human Services (HHS) today updated its guidance to hospitals on the reporting of COVID-19-related data.